SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of Novo Nordisk's office in Fremont, California
Earnings
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
February 4, 2026
 · 
3 min read
 · 
Annalee Armstrong
3D illustration of tow GLP-1 therapy autoinjectors
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Rare diseases
Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos
After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.
February 4, 2026
 · 
2 min read
 · 
Annalee Armstrong
GSK's headquarters office building in Poznan, Poland
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
FDA
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says
Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior reviewers, according to Auchincloss.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Earnings
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
February 4, 2026
 · 
1 min read
 · 
Annalee Armstrong
shopping cart loaded with pills with dollar signs around it on a light blue background
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS